Skip to main content
Figure 11 | Molecular Pain

Figure 11

From: Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain

Figure 11

During 5 months of diabetes, Western blotting (A) identified mild increased levels of Iba1 (B) in diabetic mice. As well, phosphorylated p38 MAPK was elevated during diabetes at 5 months of time (C). Sample protein blots are demonstrated in A (total of 3 sample blots identified for each marker and each intervention at the final time point). Only intranasal or intraperitoneal cannabidiol administered at the onset of diabetes was associated with suppression of Iba1 and phosphorylated p38 MAPK levels at endpoint (B, C). Multiple ANOVA tests were performed in each case, with * indicating significant difference (p < 0.05) between diabetic cohorts receiving intranasal cannabidiol and no intervention after 5 months of diabetes.

Back to article page